Alkermes plc – NASDAQ:ALKS

Add to watchlist

$29

-0.55

-1.86%

Market closed

Open in about 16 hours

+25.37%

month

+25.37%

quarter

+5.31%

year

Market Cap	4.77B
Enterprise value	4.82B

P/E	-30.04
EV/Sales	4.33
EV/EBITDA	-82.68
Price/Sales	4.24
Price/Book	4.51
PEG ratio	0.13
EPS	2.62

Revenue	1.72B
EBITDA	440.91M
Income	434.43M
Revenue Q/Q	21.82%
Revenue Y/Y	54.00%

Profit margin	-14.24%
Oper. margin	-12.8%
Gross margin	80.38%
EBIT margin	-12.8%
EBITDA margin	25.54%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Alkermes Stock Forecast

M Q Y

Last Year

$35

Potential upside: 20.68%

Analysts Price target
Financials & Ratios estimates

Alkermes plc (NASDAQ:ALKS): Profit margin
Jun 2023	617.39M	237.06M	38.4%
Sep 2023	380.93M	47.75M	12.54%
Dec 2023	377.47M	112.77M	29.88%
Mar 2024	350.37M	36.82M	10.51%

Alkermes plc (NASDAQ:ALKS): Earnings per share (EPS)
2024-02-15	0.46	0.48
2024-05-01	0.59	0.44

Alkermes plc (NASDAQ:ALKS): Debt to assets
Jun 2023	2187184000	906.74M	41.46%
Sep 2023	2279231000	923.64M	40.52%
Dec 2023	2136223000	933.53M	43.7%
Mar 2024	2123896000	869.13M	40.92%

Alkermes plc (NASDAQ:ALKS): Cash Flow
Jun 2023	215.71M	120.84M	7.83M
Sep 2023	99.70M	-119.35M	1.56M
Dec 2023	107.23M	-20.98M	-276.49M
Mar 2024	21.10M	-39.95M	-17.87M

Alkermes alternative data

Alkermes plc (NASDAQ:ALKS): Employee count
Aug 2023	2,280
Sep 2023	2,280
Oct 2023	2,280
Nov 2023	2,280
Dec 2023	2,280
Jan 2024	2,280
Feb 2024	2,280
Apr 2024	2,100
May 2024	2,100
Jun 2024	2,100
Jul 2024	2,100

Alkermes
Hedge Funds Holdings Q3 2022

87.62% -8.53%

of ALKS is owned by hedge funds

242 -21

hedge funds hold ALKS stock

143.55M -11.68M

shares is hold by hedge funds

ALKS hedge funds holdings changes

Alkermes plc (NASDAQ:ALKS): Insider trades (number of shares)
Period	Buy	Sel
Feb 2024	0	2559
Mar 2024	0	10417
Nov 2024	0	74675
Dec 2024	0	87412

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Employee Stock Option (Right to Buy)	12,452	$20.03	$249,414
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Employee Stock Option (Right to Buy)	12,090	$19.34	$233,821
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Employee Stock Option (Right to Buy)	12,044	$24.59	$296,162
Option	9 Dec 2024	LAURENCIN CATO T director director	Ordinary Shares	2,691	$22.52	$60,601
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Employee Stock Option (Right to Buy)	12,411	$26.82	$332,863
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Ordinary Shares	12,411	$26.82	$332,863
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Ordinary Shares	12,044	$24.59	$296,162
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Ordinary Shares	12,090	$19.34	$233,821
Option	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Ordinary Shares	12,452	$20.03	$249,414
Sale	9 Dec 2024	HOPKINSON CRAIG C. officer: EVP R&D,..	Ordinary Shares	61,151	$32.08	$1,961,418

Alkermes
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 1 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 15 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 25 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 26 Jul 2023	Q2 2023 Earnings Call Transcript

ALKS earnings call transcripts

Alkermes
Executives

Insider	Age	Compensation
Mr. Richard F. Pops (1962) Chairman & Chief Executive Officer	63	$2,000,000
Dr. Craig C. Hopkinson (1968) Executive Vice President of R&D and Chief Medical Officer	57	$1,020,000
Mr. David Joseph Gaffin (1972) Senior Vice President, Chief Legal Officer, Chief Compliance Officer & Sec.	53	$839,910
Mr. Michael J. Landine (1954) Senior Vice President of Corporation Devel. & Chief Risk Officer	71	$750,460

Alkermes
Latest News

Monday, 25 November 2024
16:00	Alkermes to Participate in Upcoming Investor Conferences	prnewswire.com
Sunday, 24 November 2024
09:58	Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth	seekingalpha.com
Monday, 11 November 2024
16:00	Alkermes to Participate in Two Upcoming Investor Conferences	prnewswire.com
Thursday, 7 November 2024
07:00	Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences	prnewswire.com
Friday, 25 October 2024
11:11	Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down	zacks.com
Thursday, 24 October 2024
13:04	Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript	seekingalpha.com
12:06	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say	zacks.com
09:11	Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates	zacks.com
07:00	Alkermes plc Reports Third Quarter 2024 Financial Results	prnewswire.com
Tuesday, 22 October 2024
10:21	Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures	zacks.com
Thursday, 17 October 2024
16:00	Alkermes to Report Third Quarter Financial Results on October 24, 2024	prnewswire.com
Friday, 11 October 2024
10:56	Here's Why Alkermes (ALKS) is a Strong Momentum Stock	zacks.com
Thursday, 10 October 2024
10:50	Here's Why Alkermes (ALKS) is a Strong Growth Stock	zacks.com
Wednesday, 25 September 2024
08:00	Alkermes to Host Investor Event to Review Orexin Portfolio Strategy	prnewswire.com
Monday, 23 September 2024
10:51	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term	zacks.com
07:00	Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024	prnewswire.com
Friday, 20 September 2024
10:41	Here's Why Alkermes (ALKS) is a Strong Value Stock	zacks.com
Friday, 13 September 2024
07:00	Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program	prnewswire.com
Thursday, 5 September 2024
10:45	Here's Why Alkermes (ALKS) is a Strong Growth Stock	zacks.com
Wednesday, 4 September 2024
10:41	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term	zacks.com
Wednesday, 28 August 2024
16:00	Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	prnewswire.com
Friday, 23 August 2024
12:15	Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680	zacks.com
Thursday, 22 August 2024
07:00	Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2	prnewswire.com
Tuesday, 20 August 2024
10:46	Why Alkermes (ALKS) is a Top Growth Stock for the Long-Term	zacks.com
Monday, 19 August 2024
10:40	Here's Why Alkermes (ALKS) is a Strong Value Stock	zacks.com
Friday, 16 August 2024
10:51	Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term	zacks.com
Thursday, 1 August 2024
10:45	Here's Why Alkermes (ALKS) is a Strong Growth Stock	zacks.com
Tuesday, 30 July 2024
10:41	Why Alkermes (ALKS) is a Top Value Stock for the Long-Term	zacks.com
Thursday, 25 July 2024
11:46	Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat	zacks.com
Wednesday, 24 July 2024
10:35	Alkermes (ALKS) Reports Q2 Earnings: What Key Metrics Have to Say	zacks.com

Ideas & Opinions

Seeking Alpha 1 May 2025

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
Seeking Alpha 9 Apr 2025

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
Seeking Alpha 17 May 2024

The Bottom Fishing Club: Alkermes Has Great Value And Safety
Seeking Alpha 9 Apr 2024

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Seeking Alpha 9 Apr 2024

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff
Seeking Alpha 26 Jan 2024

Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage
Seeking Alpha 20 Nov 2023

The Right Play On Intra-Cellular Therapies
Seeking Alpha 10 Nov 2023

Alkermes plc: A Spread Trade On The Spin-Off To Capture Valuations Re-Rate
Seeking Alpha 24 Aug 2023

Lybalvi: Weighing In Light, But Tipping Alkermes' Scales
Seeking Alpha 29 Mar 2023

Alkermes' Strong Pipeline Positions It For Future Growth

Frequently Asked Questions (FAQ)

What's the price of Alkermes stock today?

One share of Alkermes stock can currently be purchased for approximately $29.
When is Alkermes's next earnings date?

Unfortunately, Alkermes's (ALKS) next earnings date is currently unknown.
Does Alkermes pay dividends?

No, Alkermes does not pay dividends.
How much money does Alkermes make?

Alkermes has a market capitalization of 4.77B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 49.61% to 1.66B US dollars. Alkermes earned 355.76M US dollars in net income (profit) last year or $0.44 on an earnings per share basis.
What is Alkermes's stock symbol?

Alkermes plc is traded on the NASDAQ under the ticker symbol "ALKS".
What is Alkermes's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Alkermes?

Shares of Alkermes can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Alkermes's key executives?
Alkermes's management team includes the following people:
- Mr. Richard F. Pops Chairman & Chief Executive Officer(age: 63, pay: $2,000,000)
- Dr. Craig C. Hopkinson Executive Vice President of R&D and Chief Medical Officer(age: 57, pay: $1,020,000)
- Mr. David Joseph Gaffin Senior Vice President, Chief Legal Officer, Chief Compliance Officer & Sec.(age: 53, pay: $839,910)
- Mr. Michael J. Landine Senior Vice President of Corporation Devel. & Chief Risk Officer(age: 71, pay: $750,460)
How many employees does Alkermes have?

As Jul 2024, Alkermes employs 2,100 workers.
When Alkermes went public?

Alkermes plc is publicly traded company for more then 34 years since IPO on 16 Jul 1991.
What is Alkermes's official website?

The official website for Alkermes is alkermes.com.
How can i contact Alkermes?

Alkermes can be reached via phone at +353 1 772 8000.
What is Alkermes stock forecast & price target?

Based on 4 Wall Street analysts` predicted price targets for Alkermes in the last 12 months, the avarage price target is $35. The average price target represents a 20.68% change from the last price of $29.

Alkermes plc

alkermes.com

Exchange:

NASDAQ

Full time employees:

2,100

Industry:

Biotechnology

Sector:

Healthcare

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

+353 1 772 8000

Connaught House
Dublin, 4

CIK: 0001520262
ISIN: IE00B56GVS15
CUSIP: G01767105